<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378625</url>
  </required_header>
  <id_info>
    <org_study_id>A00096/990954</org_study_id>
    <secondary_id>2229-04-10380</secondary_id>
    <nct_id>NCT00378625</nct_id>
  </id_info>
  <brief_title>Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia</brief_title>
  <official_title>Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Internacional de Entrenamiento e Investigaciones Médicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Internacional de Entrenamiento e Investigaciones Médicas</source>
  <brief_summary>
    <textblock>
      The primary goal of this study is to quantify the benefit of adding artesunate to amodiaquine
      in treating patients with uncomplicated P. falciparum malaria, in a low transmission area in
      Colombia. The benefit will be assessed in terms of:

        -  Efficacy

        -  Tolerability

        -  Time of fever clearance

        -  Time of parasite clearance

        -  Proportion of gametocyte carriers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment failures</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>gametocyte carriage</measure>
  </primary_outcome>
  <enrollment>360</enrollment>
  <condition>Malaria,Falciparum</condition>
  <condition>Malaria</condition>
  <condition>Antimalarials</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pure P. falciparum infection

          2. parasitaemia &gt;500 and &lt;50,000 asexual parasites/μL (subsequently the lower limit was
             modified to &gt;250 asexual parasites/μL)

          3. age between 1 and 65 years old

          4. availability to return for follow-up

        Exclusion Criteria:

          1. Pregnancy

          2. history of allergy to the study drugs

          3. history of taken complete treatment with an antimalarial drug in the previous 72 hours
             or sulphas, clindamycin or tetracycline in the previous week

          4. have a medical history of untreated hypertension or chronic heart, kidney or liver
             disease

          5. present any danger signs of severe malaria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyda Osorio, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Internacional de Entrenamiento e Investigaciones Médicas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ismael Roldan and Centro de Salud San Vicente</name>
      <address>
        <city>Quibdo</city>
        <state>Choco</state>
        <zip>00</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2006</study_first_posted>
  <last_update_submitted>September 19, 2006</last_update_submitted>
  <last_update_submitted_qc>September 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

